A multicenter, international study suggests that people who have early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes within their tumors may have a lower risk of recurrence and better survival rates, even when not treated with chemotherapy.
From left to right: Geoffrey Shapiro, Leif Ellisen and Nancy Lin. Sitting below them is Kornelia Polyak.The Dana-Farber/Harvard Cancer Center, a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.
